Page 109 - 《中国药房》2025年20期

predictor of damage accrual measured by damage index tiphospholipid syndrome：a pilot open label randomized
for APS：a longitudinal study[J]. Rheumatology（Oxford）， prospective study[J]. Autoimmun Rev，2020，19（4）：
2023，62（6）：2211-2219. 102491.
[10] MOSTEIRIN N F，COMET L S，OSUNA C S，et al. Inde‐ [21] SCHMIDT-TANGUY A，VOSWINKEL J，HENRION D，
pendent validation of the adjusted GAPSS：role of throm‐ et al. Antithrombotic effects of hydroxychloroquine in pri‐
botic risk assessment in the real-life setting[J]. Lupus， mary antiphospholipid syndrome patients[J]. J Thromb
2017，26（12）：1328-1332. Haemost，2013，11（10）：1927-1929.
[11] SAMMARITANO L R. Antiphospholipid syndrome[J]. [22] BARBHAIYA M，ZUILY S，NADEN R，et al. The 2023
Best Pract Res Clin Rheumatol，2020，34（1）：101463. ACR/EULAR antiphospholipid syndrome classification
[12] DEPIETRI L，VEROPALUMBO M R，LEONE M C，et criteria[J]. Arthritis Rheumatol，2023，75（10）：1687-1702.
al. Antiphospholipid syndrome：state of the art of clinical [23] GRIEM K，FALTER T，HOLLERBACH A，et al. Associa‐
management[J]. Cardiovasc Drugs Ther，2025，39（2）： tion of specific antiphospholipid antibodies to platelet
385-404. count and thrombocytopenia[J/OL]. Thromb Haemost，
[13] ARACHCHILLAGE D J，PLATTON S，HICKEY K，et 2025[2025-03-25]. https：//www.thieme-connect.de/pro-
al. Guidelines on the investigation and management of an‐ ducts/ejournals/abstract/10.1055/a-2510-6147.
tiphospholipid syndrome[J]. Br J Haematol，2024，205 [24] TRAN V，SCHMITT A，KASTURI S. Prevalence of
（3）：855-880. heparin-induced thrombocytopenia in hospitalized patients
[14] KHAIRANI C D，BEJJANI A，PIAZZA G，et al. Direct with antiphospholipid syndrome or lupus with antiphos‐
oral anticoagulants vs vitamin K antagonists in patients pholipid antibodies[J]. Am J Med，2025，138（9）：1304-
with antiphospholipid syndromes：meta-analysis of ran‐ 1307.
domized trials[J]. J Am Coll Cardiol，2023，81（1）：16-30. [25] ERTON Z B，LEAF R K，DE ANDRADE D，et al. Throm‐
[15] PENGO V，HOXHA A，ANDREOLI L，et al. Trial of riva‐ bocytopenia and autoimmune hemolytic anemia in an‐
roxaban in antiphospholipid syndrome（TRAPS）：two- tiphospholipid antibody-positive patients： descriptive
year outcomes after the study closure[J]. J Thromb Hae‐ analysis of the antiphospholipid syndrome alliance for
most，2021，19（2）：531-535. clinical trials and international networking （APS
[16] OKUMA H，KITAGAWA Y，YASUDA T，et al. Compari‐ ACTION）clinical database and repository（“Registry”）
son between single antiplatelet therapy and combination [J]. Lupus，2025，34（6）：617-625.
of antiplatelet and anticoagulation therapy for secondary [26] ZUILY S，CERVERA R，FORET T，et al. Thrombocyto-
prevention in ischemic stroke patients with antiphospho‐ penia in antiphospholipid syndrome：is anticoagulation
lipid syndrome[J]. Int J Med Sci，2009，7（1）：15-18. and/or antiaggregation always required? [J]. Autoimmun
[17] JACKSON W G，OROMENDIA C，UNLU O，et al. Re‐ Rev，2024，23（1）：103417.
current thrombosis in patients with antiphospholipid anti‐ [27] SUN Y，ZHAO J，ZHANG P，et al. Clinical characteristics
bodies and arterial thrombosis on antithrombotic therapy and risk factors of microvascular involvement in primary
[J]. Blood Adv，2017，1（25）：2320-2324. antiphospholipid syndrome：a longitudinal single-center
[18] ATTACHAIPANICH T， AUNGSUSIRIPONG A， study in China[J]. Lupus，2019，28（13）：1558-1565.
PIRIYAKHUNTORN P，et al. Antithrombotic therapy in [28] XOURGIA E，TEKTONIDOU M G. Management of non-
antiphospholipid syndrome with arterial thrombosis：a sys‐ criteria manifestations in antiphospholipid syndrome[J].
tematic review and network meta-analysis[J]. Front Med Curr Rheumatol Rep，2020，22（9）：51.
（Lausanne），2023，10：1196800. [29] RUIZ-IRASTORZA G，TEKTONIDOU M G，KHAMASHTA
[19] COHEN H，CUADRADO M J，ERKAN D，et al. 16th in‐ M. Anticoagulant and non-anticoagulant therapy in throm‐
ternational congress on antiphospholipid antibodies task botic antiphospholipid syndrome：old drugs and new treat‐
force report on antiphospholipid syndrome treatment ment targets[J]. Rheumatology（Oxford），2024，63（SI）：
trends[J]. Lupus，2020，29（12）：1571-1593. SI96-SI106.
[20] KRAVVARITI E，KOUTSOGIANNI A，SAMOLI E，et al. （收稿日期：2025-04-08 修回日期：2025-08-21）
The effect of hydroxychloroquine on thrombosis preven‐ （编辑：张元媛）
tion and antiphospholipid antibody levels in primary an‐

中国药房 2025年第36卷第20期 China Pharmacy 2025 Vol. 36 No. 20 · 2587 ·